Biktarvy
Payments companies reported to CMS as associated with Biktarvy. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Biktarvy, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Biktarvy
These are the largest totals companies reported as associated with Biktarvy. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Joseph Gathe | Houston, TX | Infectious Disease | $174,018.86 |
| Michael Sension | Fort Lauderdale, FL | Internal Medicine | $99,976.54 |
| Moti Ramgopal | Fort Pierce, FL | Infectious Disease | $80,794.75 |
| Jay Gladstein | Los Angeles, CA | Infectious Disease | $78,782.57 |
| Jihad Slim | Newark, NJ | Infectious Disease | $77,594.36 |
| Lisa Spacek | Philadelphia, PA | Infectious Disease | $75,342.83 |
| Ben Barnett | Houston, TX | Infectious Disease | $73,612.67 |
| Shannon Fryery | Oxford, MS | Family | $72,931.96 |
| Ann Khalsa | Phoenix, AZ | Adult Medicine | $69,821.68 |
| John Hogan | Washington, DC | Gastroenterology (Internal Medicine) | $68,605.43 |
Prescribed Biktarvy?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.